These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 23288136)

  • 1. Change in subfoveal choroidal thickness in central serous chorioretinopathy following spontaneous resolution and low-fluence photodynamic therapy.
    Kang NH; Kim YT
    Eye (Lond); 2013 Mar; 27(3):387-91. PubMed ID: 23288136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Choroidal thickness following extrafoveal photodynamic treatment with verteporfin in patients with central serous chorioretinopathy.
    Pryds A; Larsen M
    Acta Ophthalmol; 2012 Dec; 90(8):738-43. PubMed ID: 21586096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subfoveal choroidal thickness after treatment of central serous chorioretinopathy.
    Maruko I; Iida T; Sugano Y; Ojima A; Ogasawara M; Spaide RF
    Ophthalmology; 2010 Sep; 117(9):1792-9. PubMed ID: 20472289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical research on one-third dose verteporfin photodynamic therapy in the treatment of chronic central serous chorioretinopathy.
    Hua L; Lin B; Hong J; Min HB; Han WL; Zhou TY; Zhang ZQ
    Eur Rev Med Pharmacol Sci; 2018 Jan; 22(2):278-284. PubMed ID: 29424884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing effects of photodynamic therapy in central serous chorioretinopathy: full-dose versus half-dose versus half-dose-half-fluence.
    Park W; Kim M; Kim RY; Park YH
    Graefes Arch Clin Exp Ophthalmol; 2019 Oct; 257(10):2155-2161. PubMed ID: 31367848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Half-fluence photodynamic therapy in chronic central serous chorioretinopathy.
    Smretschnig E; Ansari-Shahrezaei S; Hagen S; Glittenberg C; Krebs I; Binder S
    Retina; 2013 Feb; 33(2):316-23. PubMed ID: 23314238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early choriocapillaris changes after half-fluence photodynamic therapy in chronic central serous chorioretinopathy evaluated by optical coherence tomography angiography: Preliminary results.
    Demircan A; Yesilkaya C; Alkin Z
    Photodiagnosis Photodyn Ther; 2018 Mar; 21():375-378. PubMed ID: 29409857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Focal and Conventional Verteporfin Photodynamic Therapy for Chronic Central Serous Chorioretinopathy.
    Noh SR; Kang MS; Kim K; Kim ES; Yu SY
    Korean J Ophthalmol; 2019 Dec; 33(6):506-513. PubMed ID: 31833247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CHOROIDAL THICKNESS AFTER FULL-FLUENCE AND HALF-FLUENCE PHOTODYNAMIC THERAPY IN CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.
    Oh BL; Yu HG
    Retina; 2015 Aug; 35(8):1555-60. PubMed ID: 25932547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Term Outcomes of Full-Fluence and Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy.
    Son BK; Kim K; Kim ES; Yu SY
    Ophthalmologica; 2019; 241(2):105-115. PubMed ID: 30110697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy: Predisposing Factors for Visual Acuity Outcomes.
    Matušková V; Vysloužilová D; Uher M
    Semin Ophthalmol; 2018; 33(5):690-699. PubMed ID: 29252091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COMPARISON OF PHOTODYNAMIC THERAPY USING HALF-DOSE OF VERTEPORFIN OR HALF-FLUENCE OF LASER LIGHT FOR THE TREATMENT OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.
    Cheng CK; Chang CK; Peng CH
    Retina; 2017 Feb; 37(2):325-333. PubMed ID: 27429374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Choroidal thickness after half-dose verteporfin photodynamic therapy in chronic central serous chorioretinopathy].
    Zeng J; Yan YY; Ding XY; Liu R; Li JQ
    Zhonghua Yan Ke Za Zhi; 2013 Jun; 49(6):490-4. PubMed ID: 24119960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Collaborative retrospective macula society study of photodynamic therapy for chronic central serous chorioretinopathy.
    Lim JI; Glassman AR; Aiello LP; Chakravarthy U; Flaxel CJ; Spaide RF;
    Ophthalmology; 2014 May; 121(5):1073-8. PubMed ID: 24439758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcomes of half-fluence photodynamic therapy and eplerenone in chronic central serous chorioretinopathy: A comparative study.
    Manayath G; Verghese S; Ranjan R; Agrawal H; Khanna A; Narendran V; Chhablani J
    Eur J Ophthalmol; 2021 Nov; 31(6):3110-3116. PubMed ID: 33508971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of visual and anatomical outcomes of half-fluence and half-dose photodynamic therapy in eyes with chronic central serous chorioretinopathy.
    Kim YK; Ryoo NK; Woo SJ; Park KH
    Graefes Arch Clin Exp Ophthalmol; 2015 Dec; 253(12):2063-73. PubMed ID: 25616728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-fluence photodynamic therapy versus ranibizumab for chronic central serous chorioretinopathy: one-year results of a randomized trial.
    Bae SH; Heo J; Kim C; Kim TW; Shin JY; Lee JY; Song SJ; Park TK; Moon SW; Chung H
    Ophthalmology; 2014 Feb; 121(2):558-65. PubMed ID: 24268858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Half-dose vs one-third-dose photodynamic therapy for chronic central serous chorioretinopathy.
    Uetani R; Ito Y; Oiwa K; Ishikawa K; Terasaki H
    Eye (Lond); 2012 May; 26(5):640-9. PubMed ID: 22573069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of half-fluence photodynamic therapy depending on the degree of choroidal hyperpermeability in chronic central serous chorioretinopathy.
    Lim SH; Chang W; Sagong M
    Eye (Lond); 2013 Mar; 27(3):353-62. PubMed ID: 23449515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microstructural changes after half-dose photodynamic therapy in patients with chronic central serous chorioretinopathy.
    Esen E; Sizmaz S; Demircan N
    Photodiagnosis Photodyn Ther; 2021 Sep; 35():102347. PubMed ID: 34033938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.